OUR NEWS - NETWORK
The CATALIS Network Rolls Out a New Strategic Plan for 2024-2028
The CATALIS Network Rolls Out a New Strategic Plan for 2024-2028 The CATALIS Quebec Network is pleased to announce the rollout of its new 2024-2028 Strategic Plan in collaboration with its partners, the Ministry of Health and Social Services (MHSS) and the Ministry of Economy, Innovation and Energy (MEIE). An Innovative and Ambitious Strategic Plan for 2024-2028
The CATALIS Network Supports Provincial Efforts for an Even More Innovative and Productive Clinical Research Environment
The CATALIS Network Supports Provincial Efforts for an Even More Innovative and Productive Clinical Research Environment Since its inception, CATALIS Quebec’s government mandate has been to act as a neutral and agile entity for mobilizing and coordinating efforts aimed at optimizing Quebec’s clinical research environment. CATALIS has facilitated more than 280 advisory committees and working groups with members of
3 Pharmaceutical Companies Join the CATALIS Network
3 Pharmaceutical Companies Join the CATALIS Network CATALIS is pleased to welcome the pharmaceutical companies Alexion, Lilly Canada and Novo Nordisk Canada Inc. to its Network of partners. These companies join the many industry partners committed to the Network, namely Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences Canada, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda,
2 Patient Organizations Join the CATALIS Network
2 Patient Organizations Join the CATALIS Network New organizations join the CATALIS Network: Asthma Canada and Kidney Cancer Canada. They join more than 30 patient organizations and patient partners who represent the patient’s voice within the Network and contribute to CATALIS’ mission of optimizing clinical research in Quebec, in order to accelerate the development of innovative patient care for
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network CATALIS is pleased to welcome the pharmaceutical company Gilead Sciences Canada Inc. to its Network of partners. Gilead joins numerous industry partners that are actively involved in the Network: Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. These partners support
4 New Patient Organizations Join the CATALIS Network
4 New Patient Organizations Join the CATALIS Network The CATALIS Network keeps growing. Bladder Cancer Canada, and the Canadian Liver Foundation, and Fighting Blindness Canada have joined 3 patient partners and more than 30 patient organizations. Together, they represent the patient’s voice and contribute to CATALIS’ mission, which is to optimize clinical research in Quebec, in order to
The CATALIS Network Draws on the Expertise of 3 Patient Partners
The CATALIS Network Draws on the Expertise of 3 Patient Partners The CATALIS Network is delighted to rely on the support of patient partners Casandra Poitras, Raymond Vles and Catherine Wilhelmy. Catherine Wilhelmy has been a member of the Patient Advisory Committee since its inception, while Casandra Poitras and Raymond Vles are already involved in the Patient Advisory Committee
AbCellera Joins the CATALIS Network
AbCellera Joins the CATALIS Network CATALIS is delighted to welcome AbCellera to its Network of Partners. This new pharmaceutical company will strengthen the CATALIS Network by joining the other partners: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb (BMS), GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. Together, these partners support CATALIS in its mission to optimize the
Astrazeneca and Vertex Join the Catalis Network
Astrazeneca and Vertex Join the Catalis Network CATALIS Quebec is very proud to announce that pharmaceutical companies AstraZeneca and Vertex are joining the CATALIS Network. As new members, they join Abbvie, Bayer, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. Together, the partners support CATALIS in its mission to optimize the clinical research environment to accelerate the
CATALIS’ Management Being Supported by Two New Advisory Committees
CATALIS’ Management Being Supported by Two New Advisory Committees Until recently, CATALIS’ management has been guided by three main advisory committees: a patient advisory committee made up of fifteen patient and patient-partner associations, a scientific and innovation advisory committee made up of expert clinical researchers, and an operations advisory committee made up of senior representatives from health institutions, pharmaceutical
CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform
CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform CATALIS Quebec is very proud to partner with N2 Canada to provide its Network member healthcare institutions access to a shared training platform designed to ensure the conduct of high-quality research: the CITI-Canada training platform. Through this partnership, CATALIS Quebec officially becomes the new
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service
Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time. The second FAST TRACK evaluation service coordinated a Phase I oncology study
CATALIS Quebec’s Network of Partners Now Includes 23 Quebec Health Institutions
CATALIS Quebec’s Network of Partners Now Includes 23 Quebec Health Institutions In keeping with its new government mandate of bringing together clinical research stakeholders, CATALIS Quebec is pleased to announce that it is expanding the scope of its activities to a larger number of institutions in the province: it has added 23 public institutions from Quebec’s health and social
Three Major Projects Mark the Start of the Patient Advisory Committee’s Operations
Three Major Projects Mark the Start of the Patient Advisory Committee’s Operations Patient partners and 11 patient organizations representing various medical conditions are at the core of CATALIS Quebec’s new Patient Advisory Committee. This committee was mandated by CATALIS management to identify common issues and solutions that will facilitate patient engagement and increase patient participation in, and referrals to, clinical
Patient Partners and 11 Patient Organizations Have Joined CATALIS Québec
Patient Partners and 11 Patient Organizations Have Joined CATALIS Québec CATALIS Québec and its partners want the patient’s voice to be heard in all facets of clinical research in Quebec. As a result, we are now working with patient organizations and patient partners from various therapeutic fields by including them on our new patient advisory committee. In carrying out
CATALIS invites public institutions to join the network
CATALIS is launching a new call for applications to select public institutions that will receive 2 years of funding for their participation in CATALIS activities. Within the call for applications, public institutions that are members of the Table nationale des directeurs de recherche (TNDR) are invited to apply on 2 levels of clinical research activities: the implementation of automated tools
Boehringer Ingelheim and Sanofi Join the CATALIS Network
Boehringer Ingelheim and Sanofi Join the CATALIS Network New pharmaceutical industry partners are supporting CATALIS in making Quebec a world leader in clinical research. MONTREAL, May 20, 2021 —CATALIS Québec is proud to announce that two pharmaceutical companies, Boehringer Ingelheim and Sanofi, have joined its network of partners who are working together to support Quebec’s competitiveness in conducting clinical trials.
CATALIS Québec Partners with The Coolest Hotspot Initiative
Quebec is a top destination for life sciences and clinical research. To strengthen our efforts to spread this message beyond Quebec, CATALIS Québec has joined The Coolest Hotspot network.
A clinical trial to improve pancreatic cancer treatment
A team from the CHU de Québec-Université Laval has begun a clinical trial in order to develop new therapeutic options for the treatment of pancreatic adenocarcinoma, an aggressive cancer whose survival rate is less than one year.
Number of early-stage clinical studies at the CHU de Québec Research Centreabout to double
The CHU de Québec-Université Laval (CRCHU) Research Centre has worked extra hard this year to stimulate launches of early-stage clinical research projects in the Quebec City region. The Research Centre is about to double the number of clinical trials conducted in its institutions.
Discover the hematology/oncology clinical research team at the Hôpital de l’Enfant-Jésus in Quebec City
Clinical trials, cell therapies and partnerships with different specialities: the hematology/oncology research team at the Hôpital de l’Enfant-Jésus (HEJ) in Quebec City is involved in all areas where research can make a difference for its patients.
The CHUM Research Centre’s Unit for Innovative Therapies Officially Opens
On August 29th, the management team at the CHUM Research Centre officially opened its Unit for Innovative Therapies (UIT), a competitive infrastructure for early-stage clinical research in Canada.
Pharmaceutical Industry Invests in the Development of Early Clinical Research in Quebec
CATALIS’s public and private partners join forces to make Quebec a global leader in the conduct of early-stage clinical trials.
CATALIS and the McPeak-Sirois Group collaborate to promote the growth of clinical research in Quebec
The two organizations are joining forces to maximize the human and economic benefits of clinical trials province-wide.